FI3606519T3 - Ask1:n estäjäyhdisteitä ja niiden käyttötapoja - Google Patents
Ask1:n estäjäyhdisteitä ja niiden käyttötapoja Download PDFInfo
- Publication number
- FI3606519T3 FI3606519T3 FIEP18780760.7T FI18780760T FI3606519T3 FI 3606519 T3 FI3606519 T3 FI 3606519T3 FI 18780760 T FI18780760 T FI 18780760T FI 3606519 T3 FI3606519 T3 FI 3606519T3
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- heterocycle
- pharmaceutically acceptable
- group
- solvate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 10
- 229940127254 ASK1 inhibitor Drugs 0.000 title 1
- 239000012453 solvate Substances 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 101710099484 Aminopeptidase T Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026134 WO2018187506A1 (en) | 2017-04-05 | 2018-04-04 | Ask1 inhibitor compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3606519T3 true FI3606519T3 (fi) | 2024-08-09 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18780760.7T FI3606519T3 (fi) | 2017-04-05 | 2018-04-04 | Ask1:n estäjäyhdisteitä ja niiden käyttötapoja |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20210087167A1 (https=) |
| EP (1) | EP3606519B1 (https=) |
| JP (1) | JP7196093B2 (https=) |
| KR (1) | KR102665145B1 (https=) |
| CN (1) | CN110730661B (https=) |
| AR (1) | AR111407A1 (https=) |
| AU (1) | AU2018250217B2 (https=) |
| CA (1) | CA3059107A1 (https=) |
| CL (1) | CL2019002810A1 (https=) |
| CO (1) | CO2019011708A2 (https=) |
| CR (1) | CR20190503A (https=) |
| CU (1) | CU20190080A7 (https=) |
| DK (1) | DK3606519T3 (https=) |
| DO (1) | DOP2019000255A (https=) |
| EA (1) | EA201992299A1 (https=) |
| EC (1) | ECSP19078393A (https=) |
| ES (1) | ES2992084T3 (https=) |
| FI (1) | FI3606519T3 (https=) |
| HU (1) | HUE068103T2 (https=) |
| IL (1) | IL269711B (https=) |
| JO (1) | JOP20190221A1 (https=) |
| MA (1) | MA49047A (https=) |
| MX (1) | MX394098B (https=) |
| NI (1) | NI201900102A (https=) |
| NZ (1) | NZ758345A (https=) |
| PE (1) | PE20200009A1 (https=) |
| PH (1) | PH12019502288A1 (https=) |
| PL (1) | PL3606519T3 (https=) |
| PT (1) | PT3606519T (https=) |
| RU (1) | RU2019134679A (https=) |
| SG (1) | SG11201909155VA (https=) |
| SI (1) | SI3606519T1 (https=) |
| TW (1) | TWI779022B (https=) |
| WO (1) | WO2018187506A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3735404B1 (en) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| ES3004523T3 (en) | 2018-05-02 | 2025-03-12 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| PE20221283A1 (es) | 2019-12-27 | 2022-09-05 | Lupin Ltd | Compuestos triciclicos sustituidos |
| PE20230323A1 (es) | 2020-05-01 | 2023-02-22 | Pfizer | Compuestos de azalactama como inhibidores de hpk1 |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| JP7819176B2 (ja) * | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2024020458A1 (en) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Method of treating organ diseases or disorders with ask1 inhibitors |
| TW202547513A (zh) | 2024-05-06 | 2025-12-16 | 法商Ｇｅｎｆｉｔ公司 | 敗血症的治療 |
| WO2026057806A1 (en) | 2024-09-13 | 2026-03-19 | Genfit | Injectable dosage form of 2-[6-(4-cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| PL2531501T3 (pl) * | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| ES2617339T3 (es) * | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| MX2017003933A (es) * | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| US10669242B2 (en) | 2016-06-10 | 2020-06-02 | Venenum Biodesign, LLC | Clostridium difficile toxin inhibitors |
| WO2018133866A1 (zh) | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | 作为ask1抑制剂的吡啶衍生物及其制备方法和应用 |
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| EP3580224B1 (en) | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Ask1 inhibiting agents |
| CN109071498B (zh) | 2017-02-16 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| JP2020512976A (ja) | 2017-03-27 | 2020-04-30 | ファーマケア，インク． | アポトーシスシグナル調節キナーゼ１（ａｓｋ１）阻害剤化合物 |
| EP3681499A4 (en) * | 2017-09-13 | 2021-04-21 | D.E. Shaw Research, LLC | CONNECTIONS AS RAS INHIBITORS AND THEIR USE |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-04 PL PL18780760.7T patent/PL3606519T3/pl unknown
- 2018-04-04 ES ES18780760T patent/ES2992084T3/es active Active
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 SI SI201831140T patent/SI3606519T1/sl unknown
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active Active
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 MX MX2019012013A patent/MX394098B/es unknown
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en not_active Ceased
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 HU HUE18780760A patent/HUE068103T2/hu unknown
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/en active Active
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es active IP Right Grant
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
-
2024
- 2024-09-26 US US18/897,798 patent/US20250304552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3606519T3 (fi) | Ask1:n estäjäyhdisteitä ja niiden käyttötapoja | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| EA030189B8 (ru) | Аналоги 2'-хлоронуклеозидов для инфекции вгс | |
| PE20141059A1 (es) | Indazoles | |
| MX2021009764A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. | |
| EP4420732A3 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| MX373022B (es) | Inhibidores de kv1.3 y su aplicacion medica. | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| MY203060A (en) | Prophylactic or therapeutic agent for spinal muscular atrophy | |
| MX2009008540A (es) | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. | |
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MX376500B (es) | Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. | |
| TN2016000090A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors. | |
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| HK1253073A1 (zh) | 抗真菌化合物 | |
| MX2016014878A (es) | Pirazolopiridinas y pirazolopirimidinas. | |
| MX2012015120A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica. | |
| JP2016536363A5 (https=) | ||
| JP2011522866A5 (https=) | ||
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| NZ703714A (en) | 2-aminopyrazine derivatives as csf-1 r kinase inhibitors | |
| EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |